A rigorous cost-benefit assessment can help to chart a cost-effective path forward.
James P. Catania
Advertisement
James P. Catania is a managing consultant at Tunnell Consulting
Articles by James P. Catania
Executive management leadership is essential in the effective implementation of QbD.
By identifying and eliminating non-value-added activities, drug manufacturers can avoid falling into the same cost-traps in the future.
Advertisement
Latest Updated Articles
Quality by Design: The Case for Change (Part II)May 1st 2011
Quality by Design: The Case for ChangeMarch 1st 2011
How to Reduce Unnecessary Compliance CostsJuly 1st 2010
Advertisement
Advertisement
Trending on BioPharm International
1
Sanofi Begins Construction of EU-Backed Insulin Plant in Frankfurt
2
Zylidac Bio to Scale Prolific's Optogenetic Cell Line Platform to GMP
3
TaiMed’s Anti-CD4 Antibody TMB-365 Reduces HIV Viral Load in Phase 1, Supporting Long-Acting Combination Regimens
4
Akeso's Ivonescimab Enters Phase 2/3 Biliary Tract Cancer Trial in US
5